Clincosm LogoSign in Get a demo

Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain

Sponsor
University of California, San Diego (Other)
Overall Status
Recruiting
CT.gov ID
NCT03099005
Collaborator
(none)
120
Enrollment
1
Location
3
Arms
54
Anticipated Duration (Months)
2.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Acute cannabis administration is reported to alleviate HIV neuropathic pain (HIV-NP), but there is limited knowledge about the effects of cannabis constituents (delta-9 tetrahydrocannabinol/THC and cannabidiol/CBD), the consequences of long-term cannabis use, and the impact of cannabis on endocannabinoid (EC) function in people living with HIV- NP. Our objective is to address these three fundamental gaps in our knowledge by: 1) examining the acute effects of various CBD/THC products on HIV-NP, 2) utilizing a mHealth text messaging protocol, Individual Monitoring of Pain and Cannabis Taken (IMPACT) to monitor daily real-world cannabis use and changes in pain; and 3) studying the relationship between cannabinoids, EC biomarkers, and chronic neuropathic pain

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

Our objective is to assess 120 community-dwelling people living with HIV who have neuropathic pain and are currently using cannabis. These participants will be enrolled in a study that consists of two phases:

Phase 1) This will involve a cross over study involving three different doses of vaporized cannabis that contain THC and varying concentrations of CBD:

  • Low CBD session: 8 puffs of 1.6% THC + 0.09 CBD

  • Medium CBD sessions: 4 puffs of 1.6% THC + 0.09 CBD plus 4 puffs of 1.73% THC + 5.4% CBD

  • High CBD sessions: 8 puffs of 1.73% THC + 5.4% CBD

This phase will examine the acute effects of cannabis on pain intensity, blood endocannabinoid levels, and the relationship of pain with heart rate variability (HRV).

Phase 2) This phase will involve the association between dispensary-obtained cannabis and changes in pain reported via IMPACT, a mHealth text messaging program that will serve as a useful tool to monitor the relationship between pain and cannabis use. Text messaging is an effective method to modify health behaviors, monitor substance use, and track pain. Our group has recently demonstrated the feasibility of using short message service (SMS) texting to promote anti-retroviral therapy adherence and monitor daily methamphetamine (METH) use in persons living with HIV neuropathy with bipolar disorder or METH dependence.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Acutely administered CBD/THC will reduce HIV-neuropathic pain in a stair-step manner; the highest CBD dose will provide the greatest pain reduction (high CBD > medium CBD > low CBD).Acutely administered CBD/THC will reduce HIV-neuropathic pain in a stair-step manner; the highest CBD dose will provide the greatest pain reduction (high CBD > medium CBD > low CBD).
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Participants will receive vaporized cannabis using Volcano vaporizers (Storz and Bickel) with either 3.74% THC + 0.49% CBD, 3.49% THC + 4.17% CBD, or 3.11% THC + 15.76% CBD at each of three visits. Allocation assignment of visits will be assigned using a Web-based random number- generating program, "Research Randomizer" (http:// www.randomizer.org/). The allocation schedule will be kept in the pharmacy and concealed from other study personnel.
Primary Purpose:
Treatment
Official Title:
Effect of Cannabis Administration and Endocannabinoids on HIV Neuropathic Pain Primary Study - Phase 2
Actual Study Start Date :
Jul 1, 2018
Anticipated Primary Completion Date :
Sep 30, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Low CBD session

In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.6% THC + 0.09 CBD. They will then undergo experimental testing as described below under Outcome Measures.

Drug: Cannabis
vaporization of cannabis
Other Names:
  • marijuana

    		•
    Active Comparator: Medium CBD session

    In the morning, participants will inhale 8 puffs of vaporized cannabis 4 puffs will contain 1.6% THC + 0.09 CBD and 4 puffs will contain 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.

    Drug: Cannabis
    vaporization of cannabis
    Other Names:
  • marijuana

    		•
    Active Comparator: High CBD session

    In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.

    Drug: Cannabis
    vaporization of cannabis
    Other Names:
  • marijuana

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Phase 1 - numerical 11-point Pain Intensity Scale [participants will be followed for the duration of an 4 hour, single day human laboratory experiment, and the outcome will be measured once before they receive study medication and then 3 additional times during the treatment day]

      an ordinal scale

    2. Phase 2 - numerical 11-point Pain Intensity Scale [participants will be queried on a daily basis for six months using text messaging]

      participants receive interactive text questions sent once a day to their cell phone asking them to indicate their average pain level for the day on a 0 to 10 scale

    Secondary Outcome Measures

    1. Phase 1 - Patient Global Impression of Change (PGIC) [participants will be followed for the duration of an 4 hour, single day human laboratory experiment, and this outcome will be measured 3 times after study medication is provided during the treatment day]

      a 7 point ordinal scale reflective of improvement in pain

    2. Phase 1 - von Frey test [participants will be followed for the duration of an 4 hour, single day human laboratory experiment, and the outcome will be measured once before they receive study medication and then 3 additional times during the treatment day]

      The von Frey filament will be applied on the dorsum of the more painful foot until bending is observed for 3 seconds, followed by a VAS pain rating

    3. Phase 1 - Marijuana subscale (M-scale) of the Addiction Research Center Inventory (ARCI) [participants will be followed for the duration of an 4 hour, single day human laboratory experiment, and the outcome will be measured once before they receive study medication and then 3 additional times during the treatment day]

      The M -scale has 12 true/false statements describing the subjective effects of marijuana

    4. Phase 1 - Neuropsychological Assessment Battery [participants will be followed for the duration of an 4 hour, single day human laboratory experiment, and the outcome will be measured once before they receive study medication and then 3 additional times during the treatment day]

      Testing will include the Wechsler Adult Intelligence Scale (WAIS-III) Digit Symbol, Hopkins Verbal Learning Test-Revised and Grooved Pegboard Test (motor)

    5. Phase 1 - heart rate variability [participants will be followed for the duration of an 4 hour, single day human laboratory experiment, and the outcome will be measured once before they receive study medication and then 3 additional times during the treatment day]

      Heart Rate Variability (HRV) correlates with the level of pain intensity. Persons with effective analgesic treatment of chronic pain exhibited improved HRV relative to pain sufferers with ineffective treatment suggesting HRV may serve as a pain biomarker

    6. Phase 1 - store plasma samples for evaluation of THC, CBD, and endocannabinoid system biomarkers [participants will be followed for the duration of an 4 hour, single day human laboratory experiment, and the outcome will be measured once before they receive study medication and then 3 additional times during the treatment day]

      Cannabinoid and endocannabinoid levels in plasma will be quantified using a liquid chromatography-tandem mass spectrometry (LC/MS)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. the ability to provide informed consent

    2. age 18 or older

    3. HIV infection documented at the HNRP or assessed by an HIV test at screening;

    4. a diagnosis of HIV sensory neuropathy

    5. current use of cannabis

    6. the ability to describe the THC and CBD content in the products they use, i.e., obtaining cannabis from dispensaries that list THC and CBD content

    7. ability to respond to daily text message

    Exclusion Criteria:

    1. meeting criteria for current substance or alcohol dependence

    2. traumatic brain injury

    3. dementia or Alzheimer's disease

    4. psychosis

    5. a respiratory condition, i.e., pulmonary disease, that would be exacerbated by inhaling vaporized cannabis

    6. history of cardiovascular disease, including myocardial infarction or stroke;

    7. uncontrolled hypertension, defined as a systolic blood pressure greater than 160 mm Hg or a diastolic blood pressure greater than 100 mm Hg

    8. pregnancy, breastfeeding, or unwillingness to prevent pregnancy during the cannabis administration portion of the study (using birth control in female participants of child- bearing age)

    9. unwillingness or inability to receive or respond to text messages

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 UC Center for Medicinal Cannabis Research, UC San Diego San Diego California United States 92103

    Sponsors and Collaborators

    • University of California, San Diego

    Investigators

    • Principal Investigator: Brook L Henry, PhD, University of California, San Diego

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Brook Henry, Assistant Research Scientist, University of California, San Diego
    ClinicalTrials.gov Identifier:
    NCT03099005
    Other Study ID Numbers:
    • 170510
    First Posted:
    Apr 4, 2017
    Last Update Posted:
    Jan 11, 2022
    Last Verified:
    Jan 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Brook Henry, Assistant Research Scientist, University of California, San Diego
    neuropathic pain
    human immunovirus
    vaporized cannabis
    Additional relevant MeSH terms:
    Neuralgia
    Marijuana Abuse

    Study Results

    No Results Posted as of Jan 11, 2022